BioSpace News Archive

Chinese Academy of Sciences scientist recognized for his work in medicinal chemistry and drug discovery

The SanBio Group announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation for SB623 cell therapy for the treatment of chronic neurological motor deficits secondary to traumatic brain injury (TBI).

AveXis announced that new interim data from the Phase 3 SPR1NT trial in pre-symptomatic patients as well as interim data from the ongoing Phase 3 STR1VE clinical program for Zolgensma®

Medical Optometry America (MOA) is excited to announce that it has signed an agreement with Associates in Eyecare – Optometrists (AIE) under which AIE will become the nation’s first group of independent optometric practices to adopt the MOA Brand.

Baylis Medical announced key activities that will be featured at Transcatheter Cardiovascular Therapeutics 2019, the Cardiovascular Research Foundation’s 31st annual conference and premier interventional cardiovascular medicine educational meeting, in San Francisco, CA from September 25-29.

Institutional Review Board, in Puerto Rico, approved its protocol for a double-blind, placebo-controlled, efficacy, safety and tolerability study of its proprietary formulation IGC-AD1 on behavior and functionality in subjects with dementia from Alzheimer’s disease.

Spruce Biosciences, a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders, today announced positive results from a Phase 2a, multicenter, 12-week trial of tildacerfont, an investigational, oral, once-a-day corticotropin-releasing factor type-1 receptor antagonist, in development for the treatment of congenital adrenal hyperplasia (CAH).

Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, today announced that it has appointed Christine Loh, Ph.D., as Senior Vice President, Head of Biology.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced it began dosing patients in a Phase 2 clinical study to evaluate its investigational ready-to-use, fixed-ratio co-formulation of pramlintide and insulin in patients with diabetes.

MicuRx Pharmaceuticals, Inc., today announced positive top-line results from the pivotal Phase 3 clinical trial in China for its lead antibacterial drug candidate contezolid (MRX-I) in adult patients with complicated skin and soft tissue infection (cSSTI)